Cargando…

Bacteriophage-Resistant Salmonella rissen: An In Vitro Mitigated Inflammatory Response

Non-typhoid Salmonella (NTS) represents one of the major causes of foodborne diseases, which are made worse by the increasing emergence of antibiotic resistance. Thus, NTS are a significant and common public health concern. The purpose of this study is to investigate whether selection for phage-resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Capparelli, Rosanna, Cuomo, Paola, Papaianni, Marina, Pagano, Cristina, Montone, Angela Michela Immacolata, Ricciardelli, Annarita, Iannelli, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703591/
https://www.ncbi.nlm.nih.gov/pubmed/34960737
http://dx.doi.org/10.3390/v13122468
Descripción
Sumario:Non-typhoid Salmonella (NTS) represents one of the major causes of foodborne diseases, which are made worse by the increasing emergence of antibiotic resistance. Thus, NTS are a significant and common public health concern. The purpose of this study is to investigate whether selection for phage-resistance alters bacterial phenotype, making this approach suitable for candidate vaccine preparation. We therefore compared two strains of Salmonella enterica serovar Rissen: R(R) (the phage-resistant strain) and R(W) (the phage-sensitive strain) in order to investigate a potential cost associated with the bacterium virulence. We tested the ability of both R(R) and R(W) to infect phagocytic and non-phagocytic cell lines, the activity of virulence factors associated with the main Type-3 secretory system (T3SS), as well as the canonic inflammatory mediators. The mutant R(R) strain—compared to the wildtype R(W) strain—induced in the host a weaker innate immune response. We suggest that the mitigated inflammatory response very likely is due to structural modifications of the lipopolysaccharide (LPS). Our results indicate that phage-resistance might be exploited as a means for the development of LPS-based antibacterial vaccines.